Symbols / ADXN Stock $6.23 +6.31% Addex Therapeutics Ltd

Healthcare • Biotechnology • Switzerland • NCM
ADXN (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Timothy Mark Dyer
Exch · Country NCM · Switzerland
Market Cap 7.89M
Enterprise Value 6.07M
Income -6.84M
Sales 172.86K
FCF (ttm) -1.27M
Book/sh 4.81
Cash/sh 1.33
Employees 3
Insider 10d —
IPO Feb 12, 2020
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -124.60
PEG —
P/S 45.62
P/B 1.30
P/C —
EV/EBITDA -2.16
EV/Sales 35.12
Quick Ratio 1.38
Current Ratio 1.40
Debt/Eq 0.73
LT Debt/Eq —
EPS (ttm) -9.04
EPS next Y -0.05
EPS Growth —
Revenue Growth 9.50%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) —
Earnings (prior) —
ROA -20.64%
ROE -94.75%
ROIC —
Gross Margin -288.55%
Oper. Margin -49.23%
Profit Margin 0.00%
Shs Outstand 1.27M
Shs Float 1.03M
Insider Own 0.00%
Instit Own 0.05%
Short Float 0.46%
Short Ratio 1.95
Short Interest 4.98K
52W High 12.05
vs 52W High -48.30%
52W Low 5.41
vs 52W Low 15.16%
Beta 1.97
Impl. Vol. —
Rel Volume 0.14
Avg Volume 3.83K
Volume 535.00
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $5.86
Price $6.23
Change 6.31%
About

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-induced dyskinesia. The company also develops ADX71149, which is in phase 1 for undisclosed indication; and GABAB PAM for the treatment pain, anxiety, addiction, chronic cough, and overactive bladder. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the develop mGlu2 PAM compounds for the treatment of human health; and license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$6.23
Latest analyst target
3. DCF / Fair value
$-18.02
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$6.23
Low
—
High
—
Mean
—

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2024-07-31 up HC Wainwright & Co. Neutral → Buy $30
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.03
-92.58%
0.40
-74.95%
1.61
+13.39%
1.42
Operating Revenue
0.03
-92.58%
0.40
-74.95%
1.61
+13.39%
1.42
Operating Expense
2.84
-9.96%
3.16
-18.07%
3.86
-67.77%
11.96
Research And Development
0.19
-56.30%
0.44
-53.84%
0.94
-88.04%
7.88
Selling General And Administration
1.89
+12.70%
1.68
-17.52%
2.03
-37.74%
3.26
General And Administrative Expense
1.89
+12.70%
1.68
-17.52%
2.03
-37.74%
3.26
Salaries And Wages
0.39
+60.45%
0.24
+1.70%
0.24
-5.75%
0.25
Other Gand A
1.31
+8.95%
1.21
+3.69%
1.16
-17.91%
1.42
Other Operating Expenses
0.76
-11.48%
0.86
-1.63%
0.87
+7.60%
0.81
Total Expenses
2.84
-9.96%
3.16
-18.07%
3.86
-67.77%
11.96
Operating Income
-2.81
-2.15%
-2.76
-22.84%
-2.24
+78.72%
-10.54
Total Operating Income As Reported
-2.81
-2.15%
-2.76
-22.84%
-2.24
+78.72%
-10.54
EBITDA
-6.83
-47.05%
-4.65
-112.10%
-2.19
+79.05%
-10.45
Normalized EBITDA
-6.82
-46.22%
-4.66
-148.96%
-1.87
+81.62%
-10.19
Reconciled Depreciation
0.01
-96.74%
0.26
-14.98%
0.31
-5.32%
0.32
EBIT
-6.84
-39.43%
-4.91
-96.52%
-2.50
+76.83%
-10.78
Total Unusual Items
-0.01
-175.31%
0.02
+105.49%
-0.32
-20.02%
-0.26
Total Unusual Items Excluding Goodwill
-0.01
-175.31%
0.02
+105.49%
-0.32
-20.02%
-0.26
Net Income
-6.73
-195.36%
7.06
+166.84%
-10.56
+49.26%
-20.80
Pretax Income
-6.84
-39.38%
-4.91
-96.36%
-2.50
+76.86%
-10.80
Net Non Operating Interest Income Expense
-0.00
-143.09%
0.01
-90.65%
0.06
+4505.29%
0.00
Interest Expense Non Operating
0.00
-31.75%
0.00
-8.23%
0.00
-86.17%
0.03
Net Interest Income
-0.00
-143.09%
0.01
-90.65%
0.06
+4505.29%
0.00
Interest Expense
0.00
-31.75%
0.00
-8.23%
0.00
-86.17%
0.03
Interest Income Non Operating
0.00
-100.00%
0.01
-85.67%
0.06
+118.67%
0.03
Interest Income
0.00
-100.00%
0.01
-85.67%
0.06
+118.67%
0.03
Other Income Expense
-4.03
-86.39%
-2.16
-580.69%
-0.32
-20.02%
-0.26
Gain On Sale Of Security
-0.01
-175.31%
0.02
+105.49%
-0.32
-20.02%
-0.26
Tax Provision
0.00
0.00
0.00
0.00
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-6.73
-195.36%
7.06
+166.84%
-10.56
+49.26%
-20.80
Net Income From Continuing Operation Net Minority Interest
-6.84
-39.38%
-4.91
-96.36%
-2.50
+76.86%
-10.80
Net Income From Continuing And Discontinued Operation
-6.73
-195.36%
7.06
+166.84%
-10.56
+49.26%
-20.80
Net Income Continuous Operations
-6.84
-39.38%
-4.91
-96.36%
-2.50
+76.86%
-10.80
Net Income Discontinuous Operations
0.11
-99.04%
11.97
+248.52%
-8.06
+19.44%
-10.00
Normalized Income
-6.83
-38.62%
-4.93
-125.70%
-2.18
+79.29%
-10.54
Net Income Common Stockholders
-6.73
-195.36%
7.06
+166.84%
-10.56
+49.26%
-20.80
Diluted EPS
-7.20
-185.71%
8.40
+150.00%
-16.80
+69.57%
-55.20
Basic EPS
-7.20
-185.71%
8.40
+150.00%
-16.80
+69.57%
-55.20
Basic Average Shares
0.89
+9.44%
0.82
+32.04%
0.62
+64.45%
0.38
Diluted Average Shares
0.89
+9.44%
0.82
+32.04%
0.62
-9.64%
0.69
Diluted NI Availto Com Stockholders
-6.73
-195.36%
7.06
+166.84%
-10.56
+49.26%
-20.80
Depreciation Amortization Depletion Income Statement
0.01
-95.60%
0.19
+1539.70%
0.01
+33.33%
0.01
Depreciation And Amortization In Income Statement
0.01
-95.60%
0.19
+1539.70%
0.01
+33.33%
0.01
Depreciation Income Statement
0.01
-95.60%
0.19
+1539.70%
0.01
+33.33%
0.01
Earnings From Equity Interest
-4.01
-84.30%
-2.18
0.00
0.00
Insurance And Claims
0.18
-18.57%
0.23
-64.08%
0.63
-60.50%
1.59
Rent And Landing Fees
—
—
0.04
-24.78%
0.05
Rent Expense Supplemental
—
—
0.04
-24.78%
0.05
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
6.36
-40.40%
10.68
+130.04%
4.64
-43.95%
8.28
Current Assets
1.68
-52.56%
3.54
-16.37%
4.23
-45.91%
7.83
Cash Cash Equivalents And Short Term Investments
1.64
-50.91%
3.35
-13.40%
3.87
-44.45%
6.96
Cash And Cash Equivalents
1.64
-50.97%
3.34
-13.55%
3.87
-44.44%
6.96
Cash Financial
1.64
-50.97%
3.34
-13.55%
3.87
-44.44%
6.96
Other Short Term Investments
0.01
-21.03%
0.01
+666.04%
0.00
-73.21%
0.00
Receivables
0.02
+29.48%
0.02
-89.74%
0.15
-74.72%
0.60
Accounts Receivable
0.02
+29.48%
0.02
-85.94%
0.11
-73.53%
0.42
Other Receivables
—
—
0.04
-77.45%
0.18
Prepaid Assets
0.02
-90.39%
0.17
-21.82%
0.22
-19.74%
0.27
Current Deferred Assets
—
—
—
—
Other Current Assets
—
0.01
—
—
Total Non Current Assets
4.68
-34.37%
7.14
+1652.34%
0.41
-10.11%
0.45
Net PPE
0.03
-19.84%
0.04
-87.90%
0.35
-11.49%
0.40
Gross PPE
0.20
+0.00%
0.20
-95.80%
4.67
+5.89%
4.41
Accumulated Depreciation
-0.16
-5.51%
-0.15
+96.44%
-4.32
-7.62%
-4.02
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
—
0.00
-100.00%
0.01
+0.00%
0.01
Other Properties
0.08
+0.00%
0.08
-97.12%
2.94
+0.23%
2.94
Leases
0.11
+0.00%
0.11
-93.53%
1.73
+17.21%
1.47
Goodwill And Other Intangible Assets
0.00
0.00
—
—
Investments And Advances
4.13
-41.67%
7.09
0.00
—
Long Term Equity Investment
3.85
-45.71%
7.09
0.00
—
Non Current Prepaid Assets
0.01
-0.04%
0.01
-86.96%
0.05
-0.02%
0.05
Total Liabilities Net Minority Interest
1.60
+59.59%
1.00
-71.37%
3.50
+3.78%
3.37
Current Liabilities
1.20
+49.48%
0.80
-72.28%
2.89
-11.85%
3.28
Payables And Accrued Expenses
1.19
+49.89%
0.79
-66.67%
2.38
-20.42%
3.00
Payables
0.65
+134.36%
0.28
-75.98%
1.15
-17.78%
1.40
Accounts Payable
0.60
+138.03%
0.25
-74.27%
0.98
-22.89%
1.28
Other Payable
—
—
—
0.12
Current Accrued Expenses
0.54
+4.96%
0.52
-58.00%
1.24
-22.72%
1.60
Employee Benefits
0.37
+126.24%
0.16
-62.97%
0.44
0.00
Total Tax Payable
0.04
+93.35%
0.02
-86.24%
0.16
+36.18%
0.12
Current Debt And Capital Lease Obligation
0.01
+5.12%
0.01
-97.33%
0.27
-4.25%
0.29
Current Capital Lease Obligation
0.01
+5.12%
0.01
-97.33%
0.27
-4.25%
0.29
Current Deferred Liabilities
—
0.00
-100.00%
0.23
0.00
Current Deferred Revenue
—
0.00
-100.00%
0.23
0.00
Total Non Current Liabilities Net Minority Interest
0.40
+100.37%
0.20
-67.02%
0.60
+593.04%
0.09
Long Term Debt And Capital Lease Obligation
0.03
-22.14%
0.03
-50.71%
0.07
-19.13%
0.09
Long Term Capital Lease Obligation
0.03
-22.14%
0.03
-50.71%
0.07
-19.13%
0.09
Non Current Pension And Other Postretirement Benefit Plans
0.37
+126.24%
0.16
-62.97%
0.44
0.00
Non Current Deferred Liabilities
—
0.00
-100.00%
0.09
0.00
Non Current Deferred Revenue
—
0.00
-100.00%
0.09
0.00
Stockholders Equity
4.77
-50.74%
9.68
+744.83%
1.15
-76.68%
4.91
Common Stock Equity
4.77
-50.74%
9.68
+744.83%
1.15
-76.68%
4.91
Capital Stock
2.19
+18.61%
1.84
+0.00%
1.84
+59.82%
1.15
Common Stock
2.19
+18.61%
1.84
+0.00%
1.84
+59.82%
1.15
Share Issued
218.65
+18.61%
184.35
+0.00%
184.35
+59.82%
115.35
Ordinary Shares Number
117.93
+19.91%
98.34
+3.26%
95.24
+23.47%
77.13
Treasury Shares Number
100.73
+17.11%
86.01
-3.49%
89.12
+133.21%
38.21
Additional Paid In Capital
267.31
+0.35%
266.38
+0.07%
266.19
-1.23%
269.51
Retained Earnings
-360.09
-1.90%
-353.36
+1.96%
-360.42
-3.02%
-349.86
Gains Losses Not Affecting Retained Earnings
31.76
+2.24%
31.06
+4.19%
29.81
+15.70%
25.77
Treasury Stock
1.01
+16.70%
0.87
-4.38%
0.91
-85.51%
6.28
Other Equity Adjustments
31.76
+2.24%
31.06
+4.19%
29.81
+15.70%
25.77
Total Equity Gross Minority Interest
4.77
-50.74%
9.68
+744.83%
1.15
-76.68%
4.91
Total Capitalization
4.77
-50.74%
9.68
+744.83%
1.15
-76.68%
4.91
Working Capital
0.48
-82.43%
2.74
+104.22%
1.34
-70.50%
4.55
Invested Capital
4.77
-50.74%
9.68
+744.83%
1.15
-76.68%
4.91
Total Debt
0.03
-17.40%
0.04
-87.80%
0.34
-7.72%
0.37
Capital Lease Obligations
0.03
-17.40%
0.04
-87.80%
0.34
-7.72%
0.37
Net Tangible Assets
4.77
-50.74%
9.68
+744.83%
1.15
-76.68%
4.91
Tangible Book Value
4.77
-50.74%
9.68
+744.83%
1.15
-76.68%
4.91
Available For Sale Securities
0.29
—
—
—
Financial Assets
0.51
0.00
—
—
Investmentin Financial Assets
0.29
0.00
—
—
Investmentsin Associatesat Cost
3.85
-45.71%
7.09
0.00
—
Other Equity Interest
64.62
+0.00%
64.62
+0.00%
64.62
+0.00%
64.62
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-2.17
+59.60%
-5.37
+32.77%
-7.99
+51.38%
-16.44
Cash Flow From Continuing Operating Activities
-2.17
+59.60%
-5.37
+32.77%
-7.99
+51.38%
-16.44
Net Income From Continuing Operations
-6.73
-195.36%
7.06
+166.84%
-10.56
+49.26%
-20.80
Depreciation Amortization Depletion
0.01
-96.74%
0.26
-14.98%
0.31
-5.32%
0.32
Depreciation
0.01
-96.74%
0.26
-14.98%
0.31
-5.32%
0.32
Depreciation And Amortization
0.01
-96.74%
0.26
-14.98%
0.31
-5.32%
0.32
Other Non Cash Items
0.11
-72.93%
0.40
-80.99%
2.11
-45.95%
3.90
Pension And Employee Benefit Expense
-0.01
+92.42%
-0.10
-52.00%
-0.06
-449.84%
-0.01
Stock Based Compensation
—
—
—
3.68
Operating Gains Losses
3.89
+132.80%
-11.86
-18835.33%
-0.06
-449.84%
-0.01
Gain Loss On Sale Of PPE
—
—
—
0.00
Change In Working Capital
0.55
+144.72%
-1.23
-674.66%
0.21
+35.57%
0.16
Change In Receivables
-0.00
-103.41%
0.13
-70.02%
0.45
+263.22%
-0.27
Changes In Account Receivables
-0.00
-104.91%
0.09
-69.62%
0.31
+221.59%
-0.25
Change In Prepaid Assets
0.15
+193.35%
-0.16
-407.73%
0.05
-93.68%
0.84
Change In Payables And Accrued Expense
0.39
+134.14%
-1.15
-86.90%
-0.61
-43.48%
-0.43
Change In Other Working Capital
—
-0.04
-111.84%
0.32
—
Change In Other Current Assets
0.01
+168.55%
-0.01
-687.61%
0.00
-83.43%
0.01
Investing Cash Flow
-0.68
-114.65%
4.65
+67992.59%
-0.01
-330.22%
0.00
Cash Flow From Continuing Investing Activities
-0.68
-114.65%
4.65
+67992.59%
-0.01
-330.22%
0.00
Net PPE Purchase And Sale
0.00
+100.00%
-0.00
+81.39%
-0.01
-1077.62%
-0.00
Purchase Of PPE
0.00
+100.00%
-0.00
+81.39%
-0.01
-1077.62%
-0.00
Capital Expenditure
—
-0.00
+81.39%
-0.01
-1077.62%
-0.00
Net Investment Purchase And Sale
-0.80
0.00
0.00
-100.00%
0.00
Purchase Of Investment
-0.80
0.00
0.00
—
Sale Of Investment
—
0.00
0.00
-100.00%
0.00
Net Business Purchase And Sale
0.11
-97.77%
5.12
0.00
0.00
Purchase Of Business
—
-0.47
0.00
0.00
Gain Loss On Sale Of Business
-0.11
+99.18%
-13.94
0.00
0.00
Net Other Investing Changes
—
-0.47
—
—
Financing Cash Flow
1.18
+1028.37%
0.10
-98.01%
5.26
+69.68%
3.10
Cash Flow From Continuing Financing Activities
1.18
+1028.37%
0.10
-98.01%
5.26
+69.68%
3.10
Net Issuance Payments Of Debt
-0.01
+90.09%
-0.07
+73.85%
-0.28
+2.18%
-0.29
Repayment Of Debt
-0.01
+90.09%
-0.07
+73.85%
-0.28
+2.18%
-0.29
Long Term Debt Payments
-0.01
+90.09%
-0.07
+73.85%
-0.28
+2.18%
-0.29
Net Long Term Debt Issuance
-0.01
+90.09%
-0.07
+73.85%
-0.28
+2.18%
-0.29
Net Common Stock Issuance
1.20
+457.78%
0.22
-90.66%
2.30
+37.68%
1.67
Common Stock Payments
-0.03
-11.90%
-0.03
+46.34%
-0.05
-1278.00%
-0.00
Cash Dividends Paid
0.00
0.00
0.00
0.00
Repurchase Of Capital Stock
-0.03
-11.90%
-0.03
+46.34%
-0.05
-1278.00%
-0.00
Proceeds From Stock Option Exercised
0.00
+100.00%
-0.04
-101.12%
3.26
+42.12%
2.29
Net Other Financing Charges
-0.01
-168.65%
0.01
-11.57%
0.01
+101.98%
-0.52
Changes In Cash
-1.67
-167.54%
-0.62
+77.20%
-2.73
+79.49%
-13.33
Effect Of Exchange Rate Changes
-0.04
-135.30%
0.10
+127.93%
-0.36
-81.91%
-0.20
Beginning Cash Position
3.34
-13.55%
3.87
-44.44%
6.96
-66.04%
20.48
End Cash Position
1.64
-50.97%
3.34
-13.55%
3.87
-44.44%
6.96
Free Cash Flow
-2.17
+59.61%
-5.37
+32.81%
-8.00
+51.34%
-16.44
Common Stock Issuance
1.23
+410.06%
0.24
-89.75%
2.35
+40.26%
1.68
Earnings Losses From Equity Investments
4.01
+84.30%
2.18
0.00
0.00
Interest Paid CFF
-0.00
+73.74%
-0.01
+57.33%
-0.02
+55.81%
-0.05
Issuance Of Capital Stock
1.23
+410.06%
0.24
-89.75%
2.35
+40.26%
1.68
Sale Of Business
0.11
-97.77%
5.12
0.00
—
SEC Filings

No SEC filings found for this symbol (may be non-US or ticker not in SEC index).

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category